#USA #San Francisco #Biomanufacturing #Stämm #High-Throughput Bioprocessor

Stämm’s High-Throughput Bioprocessor: A New Era in Biomanufacturing

In the rapidly evolving world of biomanufacturing, Stämm has made a groundbreaking move with the introduction of their new High-Throughput Bioprocessor (HTB). Designed specifically for the needs of decentralized production, the HTB aims to address the longstanding limitations imposed by traditional centralized biomanufacturing infrastructures.

The Challenge of Conventional Biomanufacturing

Traditionally, biomanufacturing has relied on large-scale, capital-intensive setups which have struggled to keep pace with the personalized nature of advanced cell therapies. The high costs associated with equipment and the lengthy timelines to bring therapies to market hinder the accessibility of potentially life-saving treatments for patients across the globe.

As noted by Yuyo Llamazares, CEO of Stämm, the company’s vision is clear: “No patient in Alaska, São Paulo, or Nairobi should have to wait for treatment due to infrastructure constraints.” This philosophy is the driving force behind the development of the HTB, which aims to bridge the gap between scientific discovery and the rapid availability of advanced therapies.

Innovative Features of the HTB

At the core of the HTB is the bubble-free bioreactor (BFB), which stands out due to its lack of a conventional turbine. Instead of relying on bubbles or agitation to circulate nutrients, the BFB utilizes laminar flow to ensure a more gentle and efficient nutrient exchange, closely mimicking the natural capillary networks found in living tissues. This unique design eliminates shear stress and turbulence, preserving delicate cell populations that often suffer in conventional stirred tank systems.

The HTB platform supports a range of applications, facilitating continuous perfusion and streamlined formulations for tasks such as the differentiation of adherent cells and automated anti-sedimentation for suspension cultures. Its modular architecture allows for rapid scalability, moving seamlessly from 50 mL to 250 mL volumes, significantly reducing operating costs and investment barriers.

Impact on the Market and Future Prospects

The global market for cell and gene therapy manufacturing has been stifled by an infrastructure that remains predominantly centralized and heavily capitalized. The HTB’s plug-and-play design directly addresses these issues by replacing traditional stainless-steel tanks with customizable cartridges. By enabling localized production, the HTB reduces development timelines, operating costs, and opens the door for manufacturing capabilities in underserved regions.

Currently, the HTB is available for process development in research applications. Biopharmaceutical and biotechnology teams looking to evaluate Stämm’s technology for preclinical production, CAR-T therapies, or stem cell expansion workflows are encouraged to reach out directly to Stämm through their website.

Conclusion
Stämm’s innovative approach with the HTB not only paves the way for increased accessibility and efficiency in biomanufacturing but also reflects a broader trend in medicine towards personalized and decentralized care. As this technology continues to evolve, it could very well revolutionize how treatments are developed and delivered, making it an exciting frontier for both patients and healthcare providers.

For more information, potential partners can visit Stämm’s website. A comprehensive review of technical data will be released in the near future, with limited opportunities for early access partnerships.